Post-traumatic Stress Disorder Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Demographics (Adult, Children), By Distribution Channel, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global post-traumatic stress disorder treatment market size was exhibited at USD 1.26 billion in 2022 and is projected to hit around USD 2.01 billion by 2032, growing at a CAGR of 4.8% during the forecast period 2023 to 2032.

Key Pointers:

• North America dominated the PTSD treatment market and accounted for the largest revenue share of 58.9% in 2022.
• In 2022, antidepressants segment accounted for the largest share and is anticipated to maintain its position over the forecast period owing to FDA approved SSRIs such as Zoloft (sertraline) and Paxil (paroxetine)
• Based on demographics, adult segment is estimated to witness the fastest CAGR of 5.3% during the forecast period owing to presence of rising disorder incidence in adult group, major chunk of patients in this age group and increase in traumatic experiences
• The retail pharmacy segment dominated the market and accounted for the largest revenue share of 65.9% over the forecast period.
• Asia Pacific region is anticipated to experience the fastest growth over the forecast period due to an increased awareness among the population, rise in disposable income, and high disease prevalence of PTSD in developing countries

 Post-traumatic Stress Disorder Treatment Market Report Scope

The major factor driving the market includes robust late stage product pipeline and increasing R&D for development of novel therapies pertaining to treatment. Moreover, global rise in burden of post-traumatic stress disorder (PTSD) cases is primarily driving the market. For instance, according to PTSD Statistics and Facts article, about 8 million Americans are suffering from the condition in 2022.

The upsurge in incidence of post-traumatic stress disorder is such that one in 13 people develop this disorder once in lifetime. According to NCBI article, 70% of adult Americans experience at least one traumatic event out of which 20% develop PTSD due to such events. The prevalence of this condition is more common in women than in men due to sexual violence and rape victims which is the leading cause of traumatic experiences. Its prevalence rate among women is around 9.7%, compared to about 3.6% in men. Furthermore, rising incidences of natural and manmade disasters, such as the COVID-19 pandemic and the Russian-Ukraine war, further support the cases.

The increasing demand for better therapeutic options is leading to innovation in R&D, and the introduction of new therapeutic drugs, thereby creating a lucrative opportunity for market growth over the forecast period. For instance, Otsuka Pharmaceutical Development Inc.’s Brexpiprazole and Zoloft Combination is in phase 3 investigation for PTSD. Furthermore, Jazz Pharmaceuticals’ JZP150, Aptinyx’s NYX-783, and Bionomics’ BNC210 are under phase 2 clinical investigation, such factors are expected drive the space growth over the forecast period.

However, side effects associated with post-traumatic stress disorder therapeutics, such as drug abuse, is expected to restrain the space growth over the forecast period.

Post-traumatic Stress Disorder Treatment Market Segmentation